Exelixis Stock Alpha and Beta Analysis
| EXEL Stock | USD 43.63 0.53 1.20% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Exelixis. It also helps investors analyze the systematic and unsystematic risks associated with investing in Exelixis over a specified time horizon. Remember, high Exelixis' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Exelixis' market risk premium analysis include:
Beta 0.59 | Alpha 0.0382 | Risk 2.05 | Sharpe Ratio 0.0362 | Expected Return 0.0742 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Exelixis Analysis, Exelixis Valuation, Exelixis Correlation, Exelixis Hype Analysis, Exelixis Volatility, Exelixis Price History and analyze Exelixis Performance. Exelixis Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Exelixis market risk premium is the additional return an investor will receive from holding Exelixis long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Exelixis. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Exelixis' performance over market.| α | 0.04 | β | 0.59 |
Exelixis expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Exelixis' Buy-and-hold return. Our buy-and-hold chart shows how Exelixis performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Exelixis Market Price Analysis
Market price analysis indicators help investors to evaluate how Exelixis stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Exelixis shares will generate the highest return on investment. By understating and applying Exelixis stock market price indicators, traders can identify Exelixis position entry and exit signals to maximize returns.
| Price Series Summation | ||
| Price Series Division | ||
| Tanh Of Price Series | ||
| Price Floor Movement | ||
| Plus Directional Indicator | ||
| Rate of change | ||
| Simple Moving Average | ||
| Exponential Moving Average | ||
| Tristar Pattern | ||
| Harami Pattern |
Exelixis Return and Market Media
The median price of Exelixis for the period between Sun, Nov 23, 2025 and Sat, Feb 21, 2026 is 43.68 with a coefficient of variation of 3.13. The daily time series for the period is distributed with a sample standard deviation of 1.36, arithmetic mean of 43.48, and mean deviation of 1.1. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Johnson David Edward of 27532 shares of Exelixis at 43.122 subject to Rule 16b-3 | 11/25/2025 |
2 | Is It Time To Reassess Exelixis After Strong MultiYear Share Price Gains | 01/08/2026 |
3 | Exelixis, Inc. Sees Mixed Analyst Actions as Zanzalintinib Nears Commercial Launch | 01/20/2026 |
4 | Is It Too Late To Consider Exelixis After Strong Multi Year Share Gains | 02/02/2026 |
5 | Exelixis Sees Composite Rating Move Up To 96 | 02/09/2026 |
6 | Why Exelixis is One of the Best Healthcare Stocks Under 50 to Invest In | 02/10/2026 |
7 | Compared to Estimates, Exelixis Q4 Earnings A Look at Key Metrics | 02/11/2026 |
8 | Exelixis Margin Expansion To 33.7 percent Tests Skeptical Growth Narratives | 02/12/2026 |
9 | Disposition of 5430 shares by Hefti Brenda of Exelixis at 43.92 subject to Rule 16b-3 | 02/13/2026 |
10 | Disposition of 250736 shares by Michael Morrissey of Exelixis subject to Rule 16b-3 | 02/17/2026 |
11 | Monoclonal Antibodies Competitive Landscape Report 2026 Comprehensive Insights About 180 Companies and 230 Drugs by Company, Product, Stage of Development, Rout... | 02/18/2026 |
12 | Exelixis The CashGenerating Biotech That I Think Deserves a Closer Look in 2026 | 02/20/2026 |
About Exelixis Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Exelixis or other stocks. Alpha measures the amount that position in Exelixis has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2020 | 2021 | 2022 | 2023 (projected) | Payables Turnover | 1.53 | 2.18 | 1.77 | 2.15 | Days Of Inventory On Hand | 211.05 | 189.79 | 209.88 | 87.16 |
Exelixis Upcoming Company Events
As portrayed in its financial statements, the presentation of Exelixis' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Exelixis' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Exelixis' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Exelixis. Please utilize our Beneish M Score to check the likelihood of Exelixis' management manipulating its earnings.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Exelixis
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Exelixis Analysis, Exelixis Valuation, Exelixis Correlation, Exelixis Hype Analysis, Exelixis Volatility, Exelixis Price History and analyze Exelixis Performance. For more information on how to buy Exelixis Stock please use our How to buy in Exelixis Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Exelixis technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.